The estimated Net Worth of Industrial Co., Ltd Fosun is at least 3.06 百万$ dollars as of 4 December 2018. Industrial Fosun owns over 600,000 units of ContraFect Corp stock worth over 1,831,220$ and over the last 6 years Industrial sold CFRX stock worth over 1,224,000$.
Industrial has made over 1 trades of the ContraFect Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently Industrial sold 600,000 units of CFRX stock worth 1,224,000$ on 4 December 2018.
The largest trade Industrial's ever made was selling 600,000 units of ContraFect Corp stock on 4 December 2018 worth over 1,224,000$. On average, Industrial trades about 600,000 units every 0 days since 2018. As of 4 December 2018 Industrial still owns at least 7,900,000 units of ContraFect Corp stock.
You can see the complete history of Industrial Fosun stock trades at the bottom of the page.
Industrial's mailing address filed with the SEC is Hong Kong, 灣仔皇后大道東183號.
Over the last 10 years, insiders at ContraFect Corp have traded over 2,523,392$ worth of ContraFect Corp stock and bought 525,578 units worth 426,359$ . The most active insiders traders include Sol J Barer、Roger Pomerantz、Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of 16,159$. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth 1,850$.
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
ContraFect Corp executives and other stock owners filed with the SEC include: